Leading Pharmaceutical Companies Mid-day Trading with Mixed Results and also
New Patent News Announced for Crown Marketing
CORAL SPRINGS, Florida, February 14, 2013
CORAL SPRINGS, Florida, February 14, 2013 /PRNewswire/ --
FinancialNewsMedia.com reports on active HealthCare Companies experiencing
mid-day trading today with mixed results: Crown Marketing Pharmaceutical,
Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb Company (NYSE: BMY), GNC
Holdings, Inc. (NYSE: GNC) and Pfizer Inc. (NYSE: PFE).
Crown Marketing Pharmaceuticals was trading higher than normal volume by
mid-day trading over 1.5 Million Shares as the company issued news before the
markets opened today. To read the entire following press release details
along with all the recent Crown news, please go to
http://www.marketwatch.com/investing/stock/cwnm . The press release states
Crown Marketing announced today that Patents for its Controlled Drug Delivery
Technology (CDDT) have been approved and registered in South Africa. This is
the Company's second major announcement regarding the approval of new Patents
following last week's news it had also secured Patents in Norway. Crown is
continuing to secure its worldwide patent rights as it pursues novel
applications of its drug delivery technology. For more details regarding
Crown's CDDT applications, go to http://crowncddt.com/technology/
Abbott Laboratories (NYSE: ABT) engages in the discovery, development,
manufacture, and sale of health care products worldwide. It offers diagnostic
systems and tests, such as immunoassay and clinical chemistry systems; assays
for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug
monitoring, fertility, and physiological and infectious diseases. ABT was up
$0.14 per share at mid-day trading on 4.5 Million shares by 12:30pm EST.
Bristol-Myers Squibb Company (NYSE: BMY) announced this week it has entered
into a three-year collaboration agreement with Reckitt Benckiser Group plc
(LSE: RBL) for several of its over-the-counter medicines currently sold across
Latin America, primarily in Mexico and Brazil. BMY was up slightly in mid-day
trading at $36.40 per share on 4.1 Million shares by 12:30pm EST.
GNC Holdings, Inc. (NYSE: GNC), a leading global specialty retailer of health
and wellness products, today reported its financial results for the quarter
and year ended December 31, 2012. Get the full report at
http://www.marketwatch.com/investing/stock/gnc .GNC was up over 8% in
mid-day trading at $39.14 per share on 6.7 Million shares by 12:45pm EST.
Pfizer Inc. (NYSE: PFE), a biopharmaceutical company, engages in the
discovery, development, manufacture, and sale of medicines for people and
animals worldwide. It primarily offers Celebrex, Chantix/Champix, Lipitor,
Lyrica, Premarin, Pristiq, and Viagra pharmaceutical products in the
therapeutic and disease areas of Alzheimer’s disease, cardiovascular, erectile
dysfunction, genitourinary, depressive disorder, pain, respiratory, and
smoking cessation. GNC was up slightly in mid-day trading at $27.07 per share
on 14.7 Million shares by 12:55pm EST.
FinancialNewsMedia.com is aleading provider of third party publishing &
news dissemination services. If you would like more information regarding our
news coverage solutions, please visit http://www.financialnewsmedia.com
for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information: Company: FN Media Group, LLC Contact email:
email@example.com U.S. Phone: +1-(954)345-0611 URL:
Press spacebar to pause and continue. Press esc to stop.